Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover…
Articles by Marisa Wexler, MS
Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution,…
Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far…
The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic…
The school closures, at-home confinements and other safety measures necessitated by the COVID-19 pandemic have caused less anxiety among children…
Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF)…
Bacteria living in the gut are abnormally slow to develop functional abilities in infants with cystic fibrosis (CF), which…
Epicore Biosystems has launched in the U.S. a wearable patch allowing it to collect and analyze sweat for biomarker research,…
Students living with cystic fibrosis (CF) and attending or starting college, either at the undergraduate or graduate level, are invited…
Cystic Fibrosis Canada has opened an initiative called Elevate, inviting people affected by cystic…